301 Binney Street
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our team to passionately pursue excellence. We discovered, developed and are commercializing linaclotide, which is approved in the United States and a number of other countries. Our pipeline priorities include exploring further opportunities for linaclotide, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to address patient needs across the upper and lower gastrointestinal tract. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma.
282 articles with Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today provided an update on its fourth quarter and full year 2018 results and recent business activities.
Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation
Important step toward launching two independent, publicly-traded companies
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2018 investor update conference call and webcast at 8:30 a.m.
1/25/2019Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more.
Ironwood Pharmaceuticals Announces Board of Directors for Ironwood and Cyclerion, Effective Following Separation
Board members bring diverse experience tailored to the distinct opportunities and strategies of each new company
Ironwood Pharmaceuticals Initiates Phase 1 Trial of IW-6463, the First CNS-penetrant sGC Stimulator to Enter Clinical Trials
Ironwood Pharmaceuticals (Nasdaq: IRWD) today announced the initiation of a Phase 1 study evaluating IW-6463 in healthy volunteers. IW-6463 is an orally administered central nervous system (CNS)-penetrant soluble guanylate cyclase (sGC) stimulator that is being developed for the treatment of serious and orphan CNS disorders.
Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in China for the Treatment of Adults with IBS-C
Ironwood anticipates that it will launch the drug with its partner in China, AstraZeneca, in the second half of 2019.
1/11/2019Biopharma companies strengthen the leadership teams during the annual J.P. Morgan Healthcare Conference.
Dr. Shetzline will lead global product development for Ironwood following separation
Ironwood Pharmaceuticals Announces Chief Executive Officers to Lead Ironwood and Cyclerion, Effective Upon Upcoming Separation
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that the Ironwood board of directors has appointed chief executive officers (CEOs) of the two companies, effective at the time of Ironwood’s planned separation which is on track to be completed in the first half of 2019.
Ironwood Pharmaceuticals, Inc. will present a corporate update at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2018 at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco.
Ironwood and Allergan Announce Settlement with Mylan Resolving LINZESS® (linaclotide) Patent Litigation
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Mylan Pharmaceuticals, Inc. (NASDAQ: MYL) resolving patent litigations brought in response to Mylan’s abbreviated new drug applications (ANDAs) seeking approval to market generic versions of LINZESS (linaclotide) prior to the expiration of the companies’ applicable patents.
Ironwood Pharmaceuticals Inc. will present a corporate update at the 27th Annual Credit Suisse Healthcare Conference on Wednesday, November 14th, 2018 at 2:15 p.m.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a commercial biotechnology company, today provided an update on its third quarter 2018 results and recent business activities.
Ironwood Pharmaceuticals, Inc. today announced it will host its third quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, November 6, 2018.
10/22/2018Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes.
Ironwood Pharmaceuticals Presenting IW-3718 and Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the presentation of clinical data for IW-3718 and linaclotide from the company and its collaborators during the American College of Gastroenterology 2018 Annual Scientific Meeting in Philadelphia, PA, October 5
Ironwood Pharmaceuticals (NASDAQ: IRWD) will present corporate updates at two upcoming investor conferences in September: 2018 Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 1:55 p.m. ET at the Westin Copley Place in Boston. 16th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 11:10 a.m. ET at the Grand Hyatt New York.
Astellas Pharma Inc. and Ironwood Pharmaceuticals, Inc. announced that approval has been obtained in Japan for the guanylate cyclase-C receptor agonist “Linzess® Tablets 0.25 mg
Second quarter revenue increased 25% year-over-year to $81 million, driven primarily by LINZESS® (linaclotide) U.S. net sales of $192 million and commercial margin of 60%